Emcure Pharmaceuticals (EMCURE) investor relations material

Financial performance and growth

• Operating revenue exceeded USD 1 billion in FY26, with 16.6% YoY revenue growth and 33.1% PAT growth, reflecting strong operational leverage and profitability improvements.

• International business contributed 56% of group revenue, with Europe, Canada, and RoW all posting over 18% YoY growth; Europe led with 25.5% growth.

• EBITDA margin improved by 80 bps to 19.4% in FY26, and ROCE reached 23.7%, up 430 bps from FY24.

• Q1 FY27 saw 22.8% YoY revenue growth and 36.2% PAT growth, with international markets driving performance.

Strategic priorities and business model

• Growth strategy focuses on deepening the domestic franchise, scaling differentiated international portfolios, and commercializing R&D platforms.

• India business emphasizes chronic therapies, brand leadership, and science-led execution, with strong positions in women's health, cardio-metabolic, CNS, and super-specialty.

• International expansion leverages complex injectables, specialty generics, and front-end presence in key markets.

R&D and innovation

• R&D investment at 4.2% of revenue, with 548 scientists and 220 patents; focus areas include chiral molecules, iron franchise, biologics, complex injectables, and novel drug delivery systems.

• Pipeline assets target metabolics, oncology, anti-infectives, HIV, dermatology, and respiratory, with near-term launches in semaglutide, liposomal doxorubicin, and lenacapavir.